Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus SOLARAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus SOLARAZE.
ALEVE-D SINUS & COLD vs SOLARAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Solaraze (diclofenac sodium) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation and pain. In actinic keratosis, it may also induce apoptosis and decrease keratinocyte proliferation.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
Apply 0.5 mL (1 unit dose) topically to actinic keratoses twice daily for 2 to 4 weeks, then 1 week off, repeat for a total of 3 treatment cycles.
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Following topical application, the terminal elimination half-life of diclofenac from plasma is approximately 12 hours (range 8-15 hours). This reflects the slow absorption and distribution from the skin depot, with clinical relevance for twice-daily dosing.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Solaraze (diclofenac sodium 3% gel) is primarily eliminated via hepatic metabolism followed by renal excretion of metabolites. Approximately 65% of a dose is excreted in urine as conjugated metabolites, with less than 1% as unchanged drug. About 35% is eliminated in feces via biliary excretion of metabolites.
Category C
Category C
NSAID/Decongestant Combination
NSAID